Why the study?
Elucidating the protective effects of the APOE-e2 variant and their limits could offer therapeutic windows for the prevention or amelioration of Alzheimer's disease.
Does the APOE-e2 genotype improve longevity, cognition, neuroimaging markers, and Alzheimer's disease neuropathology compared to APOE-e3 and e4 genotypes in humans?
Does the APOE-e2 genotype improve longevity, cognition, neuroimaging markers, and Alzheimer's disease neuropathology compared to APOE-e3 and e4 genotypes in humans?
Answers are grounded in this paper and cite their sources.
While the APOE-e2 genotype shows a robust protective role in longevity and Alzheimer's disease neuropathologies, its effects on cognition and brain imaging are inconclusive, and it is associated with a disadvantageous cerebrovascular profile and greater risk of non-AD proteinopathies.
In this review, we comprehensively, qualitatively, and critically synthesized several features of APOE-e2, a known APOE protective variant, including its associations with longevity, cognition, and neuroimaging, and neuropathology, all in humans. If e2’s protective effects—and their limits—could be elucidated, it could offer therapeutic windows for Alzheimer’s disease (AD) prevention or amelioration. Literature examining e2 within the years 1994–2021 were considered for this review. Studies on human subjects were selectively reviewed and were excluded if observation of e2 was not specified. Effects of e2 were compared with e3 and e4, separately and as a combined non-e2 group. Our examination of existing literature indicated that the most robust protective role of e2 is in longevity and AD neuropathologies, but e2’s effect on cognition and other AD imaging markers (brain structure, function, and metabolism) were inconsistent, thus inconclusive. Notably, e2 was associated with greater risk of non-AD proteinopathies and a disadvantageous cerebrovascular profile. We identified multiple methodological shortcomings of the literature on brain function and cognition that could have contributed to inconsistent and potentially misleading findings. We make careful interpretations of existing findings and provide directions for research strategies that could effectively examine the independent and unbiased effect of e2 on AD risk.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2022) conducted a review in Alzheimer's disease. APOE-e2 genotype vs. APOE-e3, APOE-e4, and combined non-e2 genotypes was evaluated on Longevity, cognition, neuroimaging markers, and Alzheimer's disease neuropathology.
Synapse has enriched 10 related papers. Consider them for comparative context: